ABAlexander Botvinnik

Alexander Botvinnik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexander Botvinnik has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Abed Nasereddin

    Core Research Facility of the Hebrew University‐Hadassah Medical School Jerusalem Israel

    1 shared publication
  • Amit Lotan

    Hebrew University of Jerusalem

    1 shared publication
  • Bernard Lerer

    Hadassah BrainLabs Center for Psychedelic Research, Hebrew University, Jerusalem, Israel

    1 shared publication
  • Eli Pikarsky

    Department of Pathology and Immunology, The Lautenberg Center for Immunology and Cancer Research The Hebrew University Hadassah Medical School Jerusalem Israel

    1 shared publication
  • Eran Kotler

    Department of Genetics Stanford University School of Medicine Ca USA

    1 shared publication
  • Faizan Hassan

    Department of Pathology and Immunology, The Lautenberg Center for Immunology and Cancer Research The Hebrew University Hadassah Medical School Jerusalem Israel

    1 shared publication

Latest Publications

  • Open Access

    APOBEC3G protects the genome of human cultured cells and mice from radiation‐induced damage

    by Yelena Britan‐Rosich, Jing Ma, Eran Kotler, Faizan Hassan, Alexander Botvinnik, Yoav Smith, Ofra Moshel, Abed Nasereddin, Gunjan Sharma, Eli Pikarsky, et al.

    Cytosine deaminases AID/APOBEC proteins act as potent nucleic acid editors, playing important roles in innate and adaptive immunity. However, the mutagenic effects of some of these proteins compromise genomic integrity and may promote tumorigenesis. Here, we demonstrate that human APOBEC3G (A3G), in addition to its role in innate immunity, promotes repair of double-strand breaks (DSBs) in vitro and in vivo. Transgenic mice expressing A3G successfully survived lethal irradiation, whereas wild-type controls quickly succumbed to radiation syndrome. Mass spectrometric analyses identified the differential upregulation of a plethora of proteins involved in DSB repair pathways in A3G-expressing cells early following irradiation to facilitate repair. Importantly, we find that A3G not only accelerates DSB repair but also promotes deamination-dependent error-free rejoining. These findings have two implications: (a) strategies aimed at inhibiting A3G may improve the efficacy of genotoxic therapies used to cure malignant tumours; and (b) enhancing A3G activity may reduce acute radiation syndrome in individuals exposed to ionizing radiation.


  • Open Access

    Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 Receptors in the Head Twitch Response Induced by 5-Hydroxytryptophan and Psilocybin: Translational Implications

    by Orr Shahar, Alexander Botvinnik, Noam Esh-Zuntz, Michal Brownstien, Rachel Wolf, Amit Lotan, Gilly Wolf, Bernard Lerer, Tzuri Lifschytz

    There is increasing interest in the therapeutic potential of psilocybin. In rodents, the serotonin precursor, 5-hydroxytryptophan (5-HTP) and psilocybin induce a characteristic 5-HT2A receptor (5-HT2AR)-mediated head twitch response (HTR), which is correlated with the human psychedelic trip. We examined the role of other serotonergic receptors and the trace amine -associated receptor 1 (TAAR1) in modulating 5-HTP- and psilocybin-induced HTR. Male C57BL/6J mice (11 weeks, ~30 g) were administered 5-HTP, 50–250 mg/kg i.p., 200 mg/kg i.p. after pretreatment with 5-HT/TAAR1 receptor modulators, psilocybin 0.1–25.6 mg/kg i.p. or 4.4 mg/kg i.p., immediately preceded by 5-HT/TAAR1 receptor modulators. HTR was assessed in a custom-built magnetometer. 5-HTP and psilocybin induced a dose-dependent increase in the frequency of HTR over 20 min with attenuation by the 5-HT2AR antagonist, M100907, and the 5-HT1AR agonist, 8-OH-DPAT. The 5-HT2CR antagonist, RS-102221, enhanced HTR at lower doses but reduced it at higher doses. The TAAR1 antagonist, EPPTB, reduced 5-HTP- but not psilocybin-induced HTR. We have confirmed the key role of 5-HT2AR in HTR, an inhibitory effect of 5-HT1AR, a bimodal contribution of 5-HT2CR and a role of TAAR1 in modulating HTR induced by 5-HTP. Compounds that modulate psychedelic-induced HTR have important potential in the emerging therapeutic use of these compounds.